Systemic therapies in metastatic non-small-cell lung cancer with emphasis on targeted therapies: The rational approach

Current Oncology

Volumn 17, Issue 2, 2010, Pages 13-23

  Hirsh, V ^a  

^a ROYAL VICTORIA HOSPITAL   (Canada)

Author keywords

Maintenance; Metastatic; Non small cell lung cancer; NSCLC; Targeted therapies

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CEDIRANIB; CETUXIMAB; CISPLATIN; DOCETAXEL; ERLOTINIB; GEFITINIB; GEMCITABINE; IRINOTECAN; NAVELBINE; OXALIPLATIN; PACLITAXEL; PEMETREXED; PLACEBO; SORAFENIB; TAXANE DERIVATIVE; VANDETANIB;

ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DIARRHEA; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; EVIDENCE BASED MEDICINE; FATIGUE; HUMAN; LUNG NON SMALL CELL CANCER; MAINTENANCE THERAPY; METASTASIS; NEUTROPENIA; OPTIMAL DRUG DOSE; QUALITY OF LIFE; RASH; RISK BENEFIT ANALYSIS; UNSPECIFIED SIDE EFFECT;

EID: 77950577933     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: None     Document Type: Article

References (60)

1. Schiller JH. Small cell lung cancer: defining a role for emerging platinum drugs. Oncology 2002;63:105-14.
2. Stinchcombe TE, Socinski MA. Treatment paradigms for advanced stage non-small cell lung cancer in the era of multiple lines of therapy. J Thorac Oncol 2009;4:243-50.
3. Ramalingam S, Belani CP. Recent advances in targeted therapy for non-small cell lung cancer. Expert Opin Ther Targets 2007;11:245-57.
4. Schiller JH, Harrington D, Belani CP, et al. on behalf of the Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-8.
5. Baggstrom MQ, Stinchcombe TE, Fried DB, Poole C, Hensing TA, Socinski MA. Third-generation chemotherapy agents in the treatment of advanced non-small cell lung cancer: a metaanalysis. J Thorac Oncol 2007;2:845-53.
6. Abratt RP, Hart GJ. 10-Year update on chemotherapy for non-small cell lung cancer. Ann Oncol 2006;17(suppl 5):v33-6.
7. Scagliotti GV, Parikh P, von Pawel J, et al. Phase iii study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naïve patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26:3543-51.
8. Grønberg BH, Bremnes RM, Fløtten O, et al. Phase iii study by the Norwegian Lung Cancer Study Group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2009;27:3217-24.
9. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003;3:401-10.
10. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005;307:58-62.
11. Ellis LM, Hicklin DJ. vegf-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer 2008;8:579-91.
12. Inai T, Mancuso M, Hashizume H, et al. Inhibition of vascular endothelial growth factor (vegf) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol 2004;165:35-52.
13. Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase ii trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004;22:2184-91.
14. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-50.
15. Reck M, von Pawel J, Zatloukal P, et al. Phase iii trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: avail. J Clin Oncol 2009;27:1227-34.
16. Laskin J, Crinò L, Tsai C, et al. MO19390 (sail): first-line bevacizumab-based therapy in advanced non-small cell lung cancer (nsclc)-outcome by chemotherapy regimen [abstract C2.5]. J Thorac Oncol 2009;4(Suppl 1):S359. [Available online from: journals.lww.com/jto/toc/2009/09001; cited February 12, 2010]
17. Sandler A, Kong G, Strickland D, Johnson D. Treatment outcomes by tumor histology in Eastern Cooperative Group (ecog) Study E4599 of bevacizumab (bv) with paclitaxel/carboplatin (pc) for advanced non-small cell lung cancer (nsclc) [abstract 133]. J Thorac Oncol 2008;3(Suppl 4):S283. [Available online from: journals.lww.com/jto/toc/2008/11001; cited February 12, 2010]
18. Hirsh V. Emerging safety data for bevacizumab in advanced non-small-cell lung cancer. Clin Lung Cancer 2008;9(suppl 2):S62-70. [Available online at: cigjournals.metapress.com/content/d43408q34506078m/; cited February 19, 2010]
19. Crinò L, Mezger J, Griesinger F, Zhou C, Reck MM. MO19390 (sail): safety and efficacy of first-line bevacizumab (Bv)- based therapy in advanced non-small cell lung cancer (nsclc) [abstract 8043]. Proc Am Soc Clin Oncol 2009;27:417s. [Available online at: www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID=30979; cited February 12, 2010]
20. Fischbach N, Spigel D, Brahmer J, et al. on behalf of the aries Investigators. Preliminary safety and effectiveness of bevacizumab (bv) based treatment in subpopulations of patients (pts) with non-small cell lung cancer (nsclc) from the aries study: a bevacizumab (bv) treatment observational cohort study (ocs) [abstract 8040]. Proc Am Soc Clin Oncol 2009;27:416s. [Available online at: www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID=30542; cited February 12, 2010]
21. Lynch T, Patel T, Dreisbach L, et al. A randomized multicenter phase iii study of cetuximab (Erbitux) in combination with taxane/carboplatin versus taxane/carboplatin alone as first-line treatment for patients with advanced/metastatic non-small cell lung cancer (nsclc): B3-03. J Thorac Oncol 2007;2(suppl 4):S340-1.
22. Pirker R, Pereira JR, Szczesna A, et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (flex): an open-label randomised phase iii trial. Lancet 2009;373:1525-31.
23. Scagliotti GV, von Pawel J, Reck M, et al. Sorafenib plus carboplatin/paclitaxel in chemonaïve patients with stage iiib-iv non-small-cell lung cancer (nsclc): interim analysis (ia) results from the phase iii, randomized, double-blind, placebo-controlled, escape (Evaluation of Sorafenib, Carboplatin, and Paclitaxel Efficacy in NSCLC) trial. J Thor Oncol 2008;3:S97-8.
24. Krupitskaya Y, Wakelee H. Vascular endothelial growth factor pathway. J Thor Oncol 2009;4(suppl 3):S1071-3.
25. Rohr U, Augustus S, Lasserre S, Compton P, Huang J. Safety of bevacizumab in patients with metastases to the central nervous system [abstract 2007]. Proc Am Soc Clin Oncol 2009;27:88s. [Available online at: www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID=30766; cited February 12, 2010]
26. European Medicines Agency (emea), Evaluation of Medicines for Human Use. Assessment Report for Avastin. International Non-proprietary Name/Common Name: Bevacizumab. Procedure no. EMEA/H/C/582/II/0025. London, U.K.: emea; 2008. [Available online at: www.ema.europa.eu/humandocs/PDFs/EPAR/avastin/Avastin-H-582-II-25-AR.pdf; cited February 12, 2010]
27. Scagliotti G, Hanna N, Fossella F, et al. The differential efficacy of pemetrexed according to nsclc histology: a review of two phase iii studies. Oncologist 2009;14:253-63.
28. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Eng J Med 2009;361:947-57.
29. Mok T, To KF, Srimunimimit V, et al. Clinical outcomes of patients with epidermal growth factor receptor (EGFR) mutations in ipass (Iressa Pan Asia Study) [abstract B9.5]. J Thorac Oncol 2009;4(suppl 1):S351. [Available online from: journals.lww.com/jto/toc/2009/09001; cited February 12, 2010]
30. Gridelli C, Maione P, Rossi A, et al. Potential treatment options after first-line chemotherapy for advanced nsclc: maintenance treatment or early second-line? Oncologist 2009;14:137-47.
31. Fidias P, Dakhil S, Lyss A, et al. Phase iii study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 2009;27:591-8.
32. Belani C, Brodowicz T, Ciuleanu T, et al. Maintenance pemetrexed (Pem) plus best supportive care (bsc) versus placebo (Plac) plus bsc: a randomized phase iii study in advanced non-small cell lung cancer (nsclc) [abstract CRA8000]. Proc Am Soc Clin Oncol 2009;27:806s. [Available online at: www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID=33019; cited February 12, 2010]
33. Mezger J, von Pawel J, Reck M. Bevacizumab (Bv) single-agent maintenance following Bv-based chemotherapy in patients with advanced non-small cell lung cancer (nsclc): results from an exploratory analysis of the avail study [abstract e19001]. Proc Am Soc Clin Oncol 2009;27:e19001. [Available online at: www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID=32977; cited February 12, 2010]
34. Cappuzzo F, Ciuleanu T, Stelmakh L, et al. saturn: a doubleblind, randomized, phase iii study of maintenance erlotinib versus placebo following nonprogression with first-line platinum-based chemotherapy in patients with advanced nsclc [abstract 8001]. Proc Am Soc Clin Oncol 2009;27:407s. [Available online at: www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID=32756; cited February 12, 2010]
35. Miller V, O'Connor P, Soh C, Kabbinavar F, on behalf of the atlas Investigators. A randomized, double-blind, placebocontrolled, phase iiib trial (atlas) comparing bevacizumab (b) therapy with or without erlotinib (e) after completion of chemotherapy with b for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (nsclc) [abstract LBA8002]. Proc Am Soc Clin Oncol 2009;27:799s. [Available online at: www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID=30819; cited February 12, 2010]
36. Cappuzzo F, Coudert B, Wierzbicki R, et al. Efficacy and safety of erlotinib as first-line maintenance in nsclc following non-progression with chemotherapy: results from the phase iii saturn study [abstract A2.1]. J Thorac Oncol 2009;4(suppl 1):S289. [Available online from: journals.lww.com/jto/toc/2009/09001; cited February 12, 2010]
37. Patel J, Bonomi P, Socinski M, et al. Treatment rationale and study design for the PointBreak Study: a randomized, openlabel phase iii study of pemetrexed/carboplatin/bevacizumab followed by maintenance pemetrexed/bevacizumab versus paclitaxel/carboplatin/bevacizumab followed by maintenance bevacizumab in patients with stage iiib or iv nonsquamous non-small-cell lung cancer. Clin Lung Cancer 2009;10:252-6.
38. Waples J, Auerbach M, Steis R, Boccia R, Wiggans R. A phase ii study of oxaliplatin and pemetrexed plus bevacizumab in advanced non-squamous non-small cell lung cancer (an International Oncology Network study, #I-04-015) [abstract 19018]. Proc Am Soc Clin Oncol 2008;26:707s. [Available online at: www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=32137; cited February 12, 2010]
39. Grothey A, Sugrue MM, Purdie DM, et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (brite). J Clin Oncol 2008;26:5326-34.
40. Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000;18:2095-103.
41. Fossella FV. Second-line chemotherapy for non-small-cell lung cancer. Curr Oncol Rep 2000;2:96-101.
42. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase iii trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22:1589-97.
43. Shepherd FA, Rodrigues Pereira J, Tan EH, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-32.
44. Novello S, Le Chevalier T. Chemotherapy for non-small cell-lung cancer. Part 2: advanced disease. Oncology 2003;17:457-71.
45. Haura E. Treatment of advanced non-small-cell lung cancer: a review of current randomized clinical trials and an examination of emerging therapies. Cancer Control 2001;8:326-36.
46. Moyer JD, Barbacci EG, Iwata KK, et al. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res 1997;57:4838-48.
47. Pollack VA, Savage DM, Baker DA, et al. Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumour effects in athymic mice. J Pharmacol Exp Ther 1999;291:739-48.
48. Kim E, Hirsh V, Mok T, et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (interest): a randomised phase iii trial. Lancet 2008;372:1809-18.
49. Bezjak A, Tu D, Seymour L, et al. Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study br.21. J Clin Oncol 2006;24:3831-7.
50. Reck M, Mali P, Arrieta O, Gottfried M, Van Meerbeeck J. Global efficacy and safety results from the trust study of erlotinib monotherapy in > 7,000 patients with non-small-cell lung cancer (nsclc) [abstract 262P]. Ann Oncol 2008;19(suppl 8):viii100.
51. Gutierrez M, Kummar S, Allen D, et al. A phase ii study of multikinase inhibitor sorafenib in patients with relapsed non-small cell lung cancer (nsclc) [abstract 19084]. Proc Am Soc Clin Oncol 2008;26:712s. [Available online at: www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=36323; cited February 12, 2010]
52. De Boer R, Arrieta Ó, Gottfried M, et al. Vandetanib plus pemetrexed vs pemetrexed as second-line therapy in patients with advanced non-small-cell lung cancer (nsclc): a randomized, double-blind phase iii trial (zeal) [abstract 8010]. Proc Am Soc Clin Oncol 2009;27:409s. [Available online at: www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID=31867; cited February 12, 2010]
53. Natale R, Thongprasert S, Greco F, et al. Vandetanib versus erlotinib in patients with advanced non-small cell lung cancer (nsclc) after failure of at least one prior cytotoxic chemotherapy: a randomized, double-blind phase iii trial (zest) [abstract 8009]. Proc Am Soc Clin Oncol 2009;27:409s. [Available online at: www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID=31610; cited February 12, 2010]
54. Herbst R, Sun Y, Korfee S, et al. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small cell lung cancer (nsclc): a randomized, double-blind phase iii trial (zodiac) [abstract CRA8003]. Proc Am Soc Clin Oncol 2009;27:807s. [Available online at: www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID=31495; cited February 12, 2010]
55. Di Maio M, Chiodini P, Georgoulias V, et al. Single agent vs combination chemotherapy (ct) as second-line treatment of advanced non-small-cell lung cancer (nsclc): a meta-analysis of individual data of five randomized trials [abstract 8052]. Proc Am Soc Clin Oncol 2008;26:436s. [Available online at: www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=31189; cited February 12, 2010]
56. Melosky B, Agulnik J, Assi H. Retrospective practice review of metastatic non-small cell lung cancer treatment with second-line erlotinib. Curr Oncol 2008;15:279-85.
57. Yang C, Shih J, Chao T, et al. Use of BIBW 2992, a novel irreversible egfr/her2 tki, to induce regression in patients with adenocarcinoma of the lung and activating EGFR mutations: preliminary results of a single-arm phase ii clinical trial [abstract 8026]. Proc Am Soc Clin Oncol 2008;26:430s. [Available online at: www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=31779; cited February 12, 2010]
58. Herbst RS, Johnson DH, Mininberg E, et al. Phase i/ii trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the her-1/ epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J Clin Oncol 2005;23:2544-55.
59. Herbst RS, O'Neill VJ, Fehrenbacher L, et al. Phase ii study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non-small-cell lung cancer. J Clin Oncol 2007;25:4743-50.
60. Herbst R, Stern H, Amler L, et al. Biomarker evaluation in the phase iii, placebo-controlled, randomized BeTa Trial of bevacizumab and erlotinib for patients with advanced non-small cell lung cancer (nsclc) after failure of standard 1st-line chemotherapy: correlation with treatment outcomes [abstract B2.1]. J Thorac Oncol 2009;4(suppl 1):S323. [Available online from: journals.lww.com/jto/toc/2009/09001; cited February 12, 2010]